Diego Braguglia
President chez Edimer Pharmaceuticals, Inc.
Profil
Diego Braguglia is currently the President, Secretary, Treasurer & Director at Edimer Pharmaceuticals, Inc. He is also a Director at Xeltis AG, AB2 Bio SA, and iOnctura SA. Previously, he held positions as a Director at ENDOSENSE SA, Picodrill SA, CeQur SA, Amal Therapeutics SA, Sequana Medical NV, and Covalys Biosciences AG.
Dr. Braguglia is a graduate of the University of Basel and holds a doctorate degree from the University of Lausanne.
Postes actifs de Diego Braguglia
| Sociétés | Poste | Début |
|---|---|---|
VI Partners AG
 VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | Private Equity Investor | 01/01/2003 |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | President | - |
iOnctura SA
 iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Directeur/Membre du Conseil | - |
AB2 Bio SA
 AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | Directeur/Membre du Conseil | - |
Xeltis AG
 Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Directeur/Membre du Conseil | 01/01/2015 |
Anciens postes connus de Diego Braguglia
| Sociétés | Poste | Fin |
|---|---|---|
| SEQUANA MEDICAL N.V. | Directeur/Membre du Conseil | - |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Directeur/Membre du Conseil | - |
CeQur SA
 CeQur SA Medical SpecialtiesHealth Technology CeQur SA develops medical devices for diabetes patients. It offers n insulin delivery device that provides three days of consistent, basal insulin deliver along with on-demand bolus insulin. The company was founded by James L. Peterson in January 2008 and is headquartered in Horw, Switzerland. | Directeur/Membre du Conseil | - |
Picodrill SA
 Picodrill SA Miscellaneous Commercial ServicesCommercial Services Picodrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. The company was founded by M. Eric Lucien, Jean-Pierre Rosat, and Christian Schmidt on October 5, 2007 and is headquartered in Lausanne, Switzerland. | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Diego Braguglia
| University of Basel | Graduate Degree |
| University of Lausanne | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SEQUANA MEDICAL N.V. | Health Technology |
| Entreprise privées | 10 |
|---|---|
VI Partners AG
VI Partners AG Investment ManagersFinance VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland. | Finance |
ENDOSENSE SA
 ENDOSENSE SA Medical SpecialtiesHealth Technology Endosense SA operated as a medical technology company, which focused on reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The firm's flagship product was TactiCath Quartz that helped physicians to measure contact force during the catheter ablation procedure. The company was founded by Vitali Verin, Giovanni Leo, and Nicolas Aeby in 2003 and was headquartered in Geneva, Switzerland. | Health Technology |
Covalys Biosciences AG
 Covalys Biosciences AG Medical SpecialtiesHealth Technology Covalys Biosciences AG develops and produces tools for protein research. The company was founded by Patrik Siedler, Maik Kindermann, Christoph Bieri, Henri Zinsli and Nils Johnsson in June 2002 and is headquartered in Witterswil, Switzerland. | Health Technology |
Picodrill SA
Picodrill SA Miscellaneous Commercial ServicesCommercial Services Picodrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. The company was founded by M. Eric Lucien, Jean-Pierre Rosat, and Christian Schmidt on October 5, 2007 and is headquartered in Lausanne, Switzerland. | Commercial Services |
CeQur SA
CeQur SA Medical SpecialtiesHealth Technology CeQur SA develops medical devices for diabetes patients. It offers n insulin delivery device that provides three days of consistent, basal insulin deliver along with on-demand bolus insulin. The company was founded by James L. Peterson in January 2008 and is headquartered in Horw, Switzerland. | Health Technology |
Edimer Pharmaceuticals, Inc.
Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Health Technology |
Xeltis AG
Xeltis AG Medical SpecialtiesHealth Technology Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland. | Health Technology |
AB2 Bio SA
AB2 Bio SA Pharmaceuticals: MajorHealth Technology AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland. | Health Technology |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
iOnctura SA
iOnctura SA Miscellaneous Commercial ServicesCommercial Services iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland. | Commercial Services |
